anks1b Antibody

What is ANKS1B and why is it important for neuroscience research?

ANKS1B encodes AIDA-1 (Amyloid-beta protein intracellular domain-associated protein 1), a protein highly enriched at neuronal synapses that regulates synaptic plasticity. ANKS1B is critically important for neuroscience research because:

• It plays a fundamental role in brain development and synaptic function

• Heterozygous deletions in ANKS1B cause ANKS1B neurodevelopmental syndrome (ANDS)

• ANDS is characterized by autism spectrum disorder (present in >60% of patients), attention deficit/hyperactivity disorder, and speech and motor deficits

• Recent studies have revealed ANKS1B's unexpected role in oligodendrocyte maturation and myelination

• ANKS1B has been linked to small Rho family GTPases, particularly Rac1 function

This multifunctional protein represents a crucial intersection between neuronal and glial cell biology, making it a high-value target for researching neurodevelopmental disorders.

How is ANKS1B protein structure organized and what are its key functional domains?

ANKS1B protein (AIDA-1) contains several conserved domains that determine its functional capabilities:

• Ankyrin repeats: Mediate protein-protein interactions

• Sterile alpha motif (SAM) domain: Involved in protein-protein interactions

• Phosphotyrosine binding (PTB) domain: Interacts with NPxY motifs in partner proteins

The protein exists in multiple isoforms with different subcellular localizations and functions:

• Isoform 2: Participates in nucleoplasmic coilin protein interactions in neuronal cells

• Isoform 3: Regulates global protein synthesis by altering nucleolar numbers

• Isoform 4: Modulates APP processing

Understanding these structural features is essential when choosing antibodies that target specific domains or isoforms for experimental applications.

How should I choose between different anti-ANKS1B antibodies for my specific experimental application?

Selection of appropriate anti-ANKS1B antibodies should be guided by your experimental requirements:

For Western Blot applications:

• Consider antibodies validated specifically for WB with dilution ranges of 1:300-5000

• Molecular weight of ANKS1B is approximately 138 kDa , so verify that your antibody detects bands at this size

• For mouse models, select antibodies with validated mouse reactivity

For Immunohistochemistry/Immunofluorescence:

• Choose antibodies validated for IHC-P (dilution 1:200-400) or IF(IHC-P) (1:50-200)

• Consider the subcellular localization pattern expected (e.g., synaptic enrichment)

For co-immunoprecipitation studies:

• Select antibodies that don't interfere with protein-protein interactions

• Consider using antibodies to different epitopes when studying ANKS1B interaction partners

When comparing antibodies, examine validation data including western blot images and immunostaining patterns in tissues of interest. The epitope location is particularly important - for instance, antibodies targeting internal epitopes might be more suitable for denatured protein applications .

What are the optimal protocols for detecting ANKS1B/AIDA-1 in brain tissue samples?

For optimal detection of ANKS1B/AIDA-1 in brain tissue samples, consider these methodological approaches:

Tissue preparation:

• For immunoprecipitation: Fresh tissue should be rapidly dissected and homogenized in appropriate lysis buffer (e.g., 25 mM Tris pH 7.4, 150 mM NaCl, 1% Tx-100, 0.1% SDS with protease inhibitors)

• Brief sonication followed by incubation at 4°C with rocking for 1 hour improves protein extraction

Immunoprecipitation protocol:

• Incubate 500 μg of lysate with 2 μg of primary antibody overnight at 4°C

• Recover immune complexes with protein G agarose preblocked with 5% BSA/PBS

• Process immunoprecipitates by standard methods and analyze by Western blot

Western blot detection:

• SDS-PAGE under standard conditions

• Transfer to appropriate membrane

• Block with 5% non-fat milk or BSA

• Primary antibody incubation at recommended dilutions (typically 1:500-1:2000)

• Detection using fluorescence-based or chemiluminescent systems

• For quantification, normalize signal to appropriate housekeeping proteins

The search results mention successful ANKS1B detection in hippocampal lysates from P42-P45 mice, suggesting this developmental timepoint is appropriate for studying ANKS1B expression .

How can ANKS1B antibodies be used to investigate oligodendrocyte maturation and myelination deficits?

Recent research has revealed an unexpected role for ANKS1B in oligodendrocyte maturation and myelination. To investigate these processes:

For oligodendrocyte quantification:

• Use anti-ANKS1B antibodies in combination with oligodendrocyte markers (e.g., Olig2) to assess co-localization in brain sections

• Quantify Olig2-positive oligodendrocytes in regions of interest (e.g., corpus callosum) in control versus experimental conditions

For myelin evaluation:

• Combine ANKS1B antibody staining with myelin basic protein (MBP) immunostaining to evaluate myelin integrity

• Assess MBP expression in regions such as corpus callosum and cerebral cortex

For mechanistic studies on Rac1 signaling:

• Use co-immunoprecipitation with ANKS1B antibodies to pull down protein complexes

• Probe for small GTPases including Rac1 using specific antibodies (e.g., rabbit anti-Rac1 1:1,000)

• Assess Rac1 activation levels in ANKS1B-deficient models

These approaches can be particularly valuable when investigating social behavior deficits in animal models, as recent evidence suggests that clemastine fumarate, which increases oligodendrocyte precursor cell maturation, can rescue social preference deficits in ANKS1B-deficient mice .

What strategies can be used to investigate ANKS1B interactions with NMDA receptors in synaptic plasticity?

ANKS1B (AIDA-1) is a key mediator of NMDAR function and synaptic plasticity. To investigate these interactions:

Co-immunoprecipitation approach:

• Prepare hippocampal lysates as described previously

• Immunoprecipitate with anti-ANKS1B antibodies

• Probe Western blots for NMDAR subunits including GluN1, GluN2A, and GluN2B

• Use appropriate controls to verify specificity of interactions

Recommended antibodies for NMDAR detection:

• Rabbit anti-GluN2A and anti-GluN2B N-terminal antibodies (dilution 1:1000)

• Mouse anti-GluN1 N-terminal (dilution 1:1000)

Functional validation methods:

• Combine electrophysiological recordings with antibody-based visualization

• Use immunocytochemistry to assess surface expression of NMDAR subunits

• For comparative quantification, normalize immunoprecipitation signals to input signals

Recent research using conditional knockout mice has demonstrated that ANKS1B controls hippocampal synaptic transmission through regulation of NMDAR subunit composition and trafficking, highlighting the importance of proper experimental design when investigating these complex interactions .

How can I resolve specificity issues with ANKS1B antibodies in Western blot applications?

When encountering specificity issues with ANKS1B antibodies in Western blot applications, consider these troubleshooting steps:

Validation of antibody specificity:

• Compare results using multiple antibodies targeting different epitopes of ANKS1B

• Include appropriate positive controls (brain tissue) and negative controls (tissues with low ANKS1B expression)

• Use ANKS1B knockout or knockdown samples as definitive controls when available

Optimization strategies:

• Titrate antibody concentration (recommended range 1:300-5000 for Western blot)

• Modify blocking conditions (try both 5% BSA and 5% non-fat milk)

• Adjust incubation time and temperature

• Consider different detection systems (chemiluminescence versus fluorescence-based)

ANKS1B-specific considerations:

• Be aware of potential cross-reactivity with the paralog ANKS1A due to similar domain structure

• Consider testing for compensatory upregulation of ANKS1A when studying ANKS1B knockdown

• Note that ANKS1B has multiple isoforms which may appear as bands of different molecular weights

Some studies have successfully used specific monoclonal antibodies generated to distinct epitopes (KRILASLGDR, PIGHDGYHPT, and KSVQIDPSEQ) for increased specificity . Consider adopting similar approaches for critical applications.

How should experimental conditions be modified when studying ANKS1B in different neural cell populations?

ANKS1B is expressed in multiple neural cell types, requiring tailored experimental approaches:

For neuronal populations:

• Use higher detergent concentrations (0.5-1% Triton X-100) for effective protein extraction from postsynaptic densities

• Consider subcellular fractionation to isolate postsynaptic density (PSD) enriched fractions using established protocols

• Co-stain with neuronal markers (e.g., NeuN, MAP2) to confirm cell-type specificity

For oligodendroglial populations:

• Use gentler lysis conditions to preserve membrane-associated proteins

• Co-stain with oligodendrocyte lineage markers (Olig2 for all oligodendrocyte lineage cells, MBP for mature oligodendrocytes)

• Consider stage-specific markers to distinguish oligodendrocyte precursors from mature cells

For developmental studies:

• Carefully select age-appropriate time points (P42-P45 has been used successfully for hippocampal studies)

• Consider regional differences in expression (e.g., corpus callosum versus cortex)

• Use Cre-driver lines for cell-type specific manipulation (e.g., CaMKIIα-Cre for forebrain neurons, oligodendrocyte-specific Cre for glial studies)

When comparing different neural populations, consistent protein extraction and normalization are critical for accurate interpretation of results.

How can ANKS1B antibodies be utilized to investigate links between myelination deficits and social behavior abnormalities?

Recent discoveries linking ANKS1B to both myelination and social behaviors offer exciting research opportunities:

Experimental approaches:

• Combine behavioral assays (social preference tests) with immunohistochemical analysis using ANKS1B antibodies

• Compare ANKS1B/AIDA-1 expression in brain regions associated with social behavior across development

• Establish correlations between white matter integrity (measured by MBP staining) and behavioral metrics

Advanced tissue analysis:

• Use co-immunoprecipitation with ANKS1B antibodies to identify cell-type specific interacting partners

• Employ proteomics to analyze the ANKS1B interactome in oligodendrocytes versus neurons

• Develop proximity labeling approaches to identify ANKS1B-associated proteins in intact tissue

Therapeutic investigation:

• Evaluate changes in ANKS1B expression/localization following treatment with compounds that promote myelination (e.g., clemastine fumarate)

• Compare Rac1 activation in oligodendrocytes before and after treatment interventions

• Use ANKS1B antibodies to track protein localization changes during oligodendrocyte maturation

This research direction is particularly promising as evidence suggests that clemastine, an antihistamine that increases oligodendrocyte precursor cell maturation, can rescue social preference deficits in 7-month-old ANKS1B-deficient mice, potentially identifying a new therapeutic avenue for ANDS patients .

What methodological approaches are recommended for investigating ANKS1B's role in drug response and pharmacogenomics?

ANKS1B has emerged as a significant factor in drug response, particularly for antipsychotics and other CNS therapeutics. To investigate these connections:

Expression analysis approaches:

• Use ANKS1B antibodies to quantify protein expression in neuronal/glial cultures before and after drug treatment

• Employ phospho-specific antibodies (if available) to assess drug-induced post-translational modifications

• Compare ANKS1B expression patterns between responders and non-responders to specific treatments

Functional validation methods:

• Combine ANKS1B knockout/knockdown with drug response assays

• Utilize patient-derived induced pluripotent stem cells (iPSCs) to create neuronal models for drug testing

• Correlate drug efficacy with ANKS1B genotype/expression levels

Protein interaction studies:

• Use co-immunoprecipitation with ANKS1B antibodies to assess drug-induced changes in protein-protein interactions

• Focus on pathways already implicated, such as NMDAR function, small GTPase signaling, and oligodendrocyte maturation

• Consider interactions between ANKS1B and downstream effectors of therapeutic compounds

As ANKS1B has been associated with response to antipsychotics like olanzapine (p = 3.0 × 10^-4) and other CNS drugs, these methodological approaches could provide important insights into mechanisms of therapeutic response and potentially guide personalized treatment strategies .

What are the best practices for quantifying ANKS1B expression levels across different experimental models?

For consistent and reliable quantification of ANKS1B expression:

Western blot quantification:

• Use standardized loading controls appropriate for your experimental context (e.g., GAPDH, β-actin, or tubulin)

• For brain tissue specifically, rat anti-tubulin (1:1,000) has been successfully used

• Always normalize ANKS1B signals to loading controls

• Use technical replicates (at least duplicates) and multiple biological replicates (n≥3)

• Employ software such as ImageJ for densitometric analysis

qPCR approaches:

• Use validated housekeeping genes such as HPRT1, SRP14, and OAZ1 for normalization

• Include both technical duplicates and biological triplicates

• Use appropriate qPCR primers (examples from literature include: forward, 5′-AGTTGCCAGCCATCTGTTGT-3′, reverse, 5′-GGGTTCCGGATCAGCTTGAT-3′)

• Calculate relative expression using the 2^-ΔΔCt method

Statistical analysis:

• Use appropriate statistical tests (e.g., t-test for two groups, ANOVA for multiple groups)

• Report both p-values and effect sizes

• Consider using specialized statistical software (e.g., JMP 16) for complex analyses

When comparing across models, maintain consistent experimental conditions including tissue collection, protein extraction methods, and quantification approaches to minimize technical variability.

How can researchers integrate ANKS1B antibody-based findings with genetic and functional data in neurodevelopmental disorder research?

Integrating multi-modal data provides deeper insights into ANKS1B's role in neurodevelopmental disorders:

Data integration strategies:

• Correlate protein expression/localization (antibody-based) with genetic variants (sequencing data)

• Connect protein interaction partners (co-immunoprecipitation) with pathway analysis (bioinformatics)

• Link cellular phenotypes (immunohistochemistry) with behavioral outputs (animal models)

Multi-level experimental design:

• Start with patient genotyping to identify ANKS1B variants

• Generate cellular models using patient-derived iPSCs

• Use ANKS1B antibodies to assess protein expression/localization in these models

• Create equivalent genetic modifications in animal models

• Validate cellular findings in animal tissues using the same antibodies

Specific methodological approaches:

• For behavioral studies in animal models, use ANKS1B antibodies to correlate protein expression with specific behavioral deficits

• In patient samples, combine genetic information with protein studies when tissue is available

• For pharmacological studies, track ANKS1B expression/interactions in response to treatments that rescue behavioral phenotypes

This integrated approach has been successfully employed in studies of ANKS1B haploinsufficiency syndrome, where patient genetic information, iPSC-derived neurons, animal models, and pharmacological interventions collectively demonstrated ANKS1B's critical role in neurodevelopment and behavior .